Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$296.85 +2.2%	$281.37	$253.30 ▼ $346.85	$159.62B	0.49	2.84 million shs	2.29 million shs
BIIB Biogen	$133.19 +2.4%	$126.09	$110.04 ▼ $238.00	$19.52B	0.14	1.43 million shs	1.47 million shs
BNTX BioNTech	$108.26 +0.7%	$102.94	$76.53 ▼ $131.49	$26.02B	1.29	940,523 shs	998,480 shs
GILD Gilead Sciences	$111.51 -0.2%	$106.65	$66.01 ▼ $119.96	$138.71B	0.29	7.68 million shs	5.99 million shs
MRNA Moderna	$30.28 +5.5%	$26.52	$23.15 ▼ $129.39	$11.71B	1.85	8.65 million shs	14.69 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+4.05%	+4.70%	+1.22%	-4.97%	-6.59%
BIIB Biogen	+3.57%	+2.98%	-0.79%	-0.95%	-43.88%
BNTX BioNTech	+0.98%	+2.30%	+12.33%	+15.21%	+36.38%
GILD Gilead Sciences	+0.78%	+4.23%	+1.25%	-0.14%	+62.78%
MRNA Moderna	+3.99%	+7.05%	+8.02%	+3.50%	-75.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.3262 of 5 stars	2.2	2.0	3.3	3.9	3.9	2.5	0.6
BIIB Biogen	4.9602 of 5 stars	4.2	5.0	0.0	3.7	3.3	1.7	2.5
BNTX BioNTech	2.4867 of 5 stars	4.4	2.0	0.0	0.0	1.8	0.8	0.0
GILD Gilead Sciences	4.8387 of 5 stars	1.4	3.0	4.2	4.1	4.0	2.5	3.1
MRNA Moderna	4.3556 of 5 stars	4.0	2.0	0.0	4.6	1.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.82	3.69% Upside
BIIB Biogen	2.38	Hold	$188.48	41.51% Upside
BNTX BioNTech	2.83	Moderate Buy	$137.86	27.34% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	-0.86% Downside
MRNA Moderna	2.04	Hold	$46.61	53.93% Upside

Current Analyst Ratings Breakdown

Latest AMGN, GILD, MRNA, BIIB, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/25/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$205.00 ➝ $213.00
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.78	$32.30 per share	9.19	$10.93 per share	27.16
BIIB Biogen	$9.68B	2.02	$24.53 per share	5.43	$114.71 per share	1.16
BNTX BioNTech	$2.98B	8.74	N/A	N/A	$87.61 per share	1.24
GILD Gilead Sciences	$28.75B	4.82	$6.91 per share	16.14	$15.44 per share	7.22
MRNA Moderna	$3.24B	3.62	N/A	N/A	$28.33 per share	1.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	27.08	13.88	2.53	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	13.15	8.07	1.00	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.48	13.75	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)

Latest AMGN, GILD, MRNA, BIIB, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.21%	N/A	86.86%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.83%	N/A	66.53%	10 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Latest AMGN, GILD, MRNA, BIIB, and BNTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
BIIB Biogen	0.27	1.44	1.01
BNTX BioNTech	0.01	10.18	10.02
GILD Gilead Sciences	1.16	1.37	1.23
MRNA Moderna	N/A	4.22	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
BNTX BioNTech	15.52%
GILD Gilead Sciences	83.67%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
BIIB Biogen	0.18%
BNTX BioNTech	19.20%
GILD Gilead Sciences	0.27%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	534.00 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable

AMGN, GILD, MRNA, BIIB, and BNTX Headlines

Recent News About These Companies

Moderna reports positive phase 3 data for mRNA seasonal flu vaccine

2 hours ago | healio.comH

RFK Jr. Just Did The Unexpected. He Helped Moderna.

4 hours ago | investors.com

Investors Purchase Large Volume of Call Options on Moderna (NASDAQ:MRNA)

5 hours ago | marketbeat.com

Moderna's new flu shot shows strong results in older adults

July 2 at 11:03 AM | msn.com

Moderna's flu-COVID combo shot will test RFK Jr.'s vaccine regulators

July 2 at 11:03 AM | msn.com

Moderna says mRNA flu vaccine sailed through trial, beating standard shot

July 2 at 11:03 AM | arstechnica.comA

Moderna flu shot outperforms marketed vaccines in pivotal late-stage trial

July 1 at 1:04 PM | thesiliconreview.comT

Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot

July 1 at 1:04 PM | biospace.comB

Moderna’s New Flu Shot Shows Strong Results in Older Adults

July 1 at 1:04 PM | usnews.com

Moderna Stock Gains on Encouraging Flu Vaccine Data

July 1 at 10:20 AM | zacks.com

The U.S. must invest in mRNA vaccines against pandemic influenza viruses now

July 1 at 8:03 AM | statnews.comS

Moderna flu vaccine shows superior results in phase 3 study

July 1 at 8:03 AM | pharmatimes.comP

13,644 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Diversified Trust Co

July 1 at 4:26 AM | marketbeat.com

Spire Wealth Management Sells 17,807 Shares of Moderna, Inc. (NASDAQ:MRNA)

July 1 at 3:55 AM | marketbeat.com

Pharmalittle: We’re reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more

July 1 at 3:02 AM | statnews.comS

Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Brokerages

July 1 at 2:47 AM | marketbeat.com

Moderna flu vaccine trial results clear path for combo shot

June 30 at 10:01 PM | beckershospitalreview.comB

Moderna shines spotlight on new flu vaccine data

June 30 at 5:01 PM | pharmaphorum.comP

Moderna’s flu vaccine hits goal, paving way for combo shot

June 30 at 5:01 PM | bostonglobe.comB

Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA

June 30 at 5:01 PM | fiercebiotech.comF

Moderna’s mRNA flu shot outperforms current standard at Phase III

June 30 at 5:01 PM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMGN, GILD, MRNA, BIIB, and BNTX Company Descriptions

Amgen NASDAQ:AMGN

$296.85 +6.33 (+2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$293.82 -3.03 (-1.02%)

As of 05:29 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$133.19 +3.12 (+2.40%)

Closing price 04:00 PM Eastern

Extended Trading

$133.61 +0.42 (+0.32%)

As of 05:16 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$108.26 +0.75 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$108.38 +0.11 (+0.11%)

As of 05:19 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Gilead Sciences NASDAQ:GILD

$111.51 -0.22 (-0.20%)

Closing price 04:00 PM Eastern

Extended Trading

$111.65 +0.14 (+0.13%)

As of 05:36 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$30.28 +1.59 (+5.54%)

Closing price 04:00 PM Eastern

Extended Trading

$30.36 +0.08 (+0.28%)

As of 05:37 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time